Teva announces successful acquisition of Labrys

JERUSALEM — Teva Pharmaceutical Industries on Monday announced that its acquistion of Labrys has been completed. The acquisition brings to Teva LBR-101, which is currently in phase-2b clinical trials for prevention of chronic and episodic migraines.



“We are pleased to finalize this acquisition. It’s an exciting opportunity to develop a much-needed treatment option for people suffering from the impact of chronic and episodic migraines. The CGRP pathway is scientifically robust, the molecule has the right specifications to deliver on its clinical promise, and the patient population is both large and underserved. This could make a real and meaningful difference to patients’ lives,” said Michael Hayden, Teva’s president of global R&D and chief scientific officer.



The company's acquisition of LBR-101 joins Teva's acquisition of Zecuity, an iontophoretic patch that delivers sumatriptan via the skin and is used for the acute treatment of migraine.